A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- 12 Dec 2017 Results exploring effect of single agent carfilzomib on bone metabolism and disease response, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 29 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 12 May 2016 Planned End Date changed from 1 Sep 2015 to 1 Oct 2016.